Evidence map›Paper›PMID 36160725›Full record

ArticlePublic health action2022

Improving TB case notification and treatment coverage through data use.

O O Chijioke-Akaniro, E Ubochioma, A Omoniyi, O Fashade, O Olarewaju, S Asuke, E C Aniwada, A N Uwaezuoke, J Sseskitooleko, N Workneh and 4 more

Abstract read
In one paragraph

Article in Public health action, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

O O Chijioke-AkaniroNational Tuberculosis, Leprosy and Buruli Ulcer Control Programme, Abuja, Nigeria.
E UbochiomaNational Tuberculosis, Leprosy and Buruli Ulcer Control Programme, Abuja, Nigeria.
A OmoniyiWorld Health Organization Country Office, Nigeria.
O FashadeNational Tuberculosis, Leprosy and Buruli Ulcer Control Programme, Abuja, Nigeria.
O OlarewajuNational Tuberculosis, Leprosy and Buruli Ulcer Control Programme, Abuja, Nigeria.
S AsukeBingham University, New Karu, Nigeria.
E C AniwadaUniversity of Nigeria Teaching Hospital, Ituku Ozalla, Enugu, Nigeria.
A N UwaezuokeUniversity of Nigeria Teaching Hospital, Ituku Ozalla, Enugu, Nigeria.
J SseskitoolekoThe Global Funds to Fight AIDS, Tuberculosis and Malaria, Geneva, Switzerland.
N WorknehThe Global Funds to Fight AIDS, Tuberculosis and Malaria, Geneva, Switzerland.
E MasiniThe Global Funds to Fight AIDS, Tuberculosis and Malaria, Geneva, Switzerland.
B MorrisThe Global Funds to Fight AIDS, Tuberculosis and Malaria, Geneva, Switzerland.
A LawansonNational Tuberculosis, Leprosy and Buruli Ulcer Control Programme, Abuja, Nigeria.
C AnyaikeNational Tuberculosis, Leprosy and Buruli Ulcer Control Programme, Abuja, Nigeria.

Funding

World Health Organization 001
6 · The paper itself

Abstract

backgroundThis was a study on national TB data.

objectiveTo assess improvement in TB case notification and treatment coverage through improved data use for action in Nigeria.

designWe analysed pre- and post-intervention secondary TB programme data comprising data on increased supervisory visits, incentives for health workers, DOTS expansion, outreaches and geo-code monitoring. Trend analysis was performed using Cochran-Armitage χ

resultsCase-finding increased from 104,904 cases in 2017 to 138,591 in 2020. There was an increase of 2.0% from 2017 to 2018, 13.0% in 2018 to 2019 and 15.0% in 2019 to 2020 (

conclusionTB service expansion, improved monitoring and the use of data for decision making are key in increasing TB treatment coverage.

Indexed as

programmesecondary datatuberculosis services

Identifiers

PMID36160725
PMCPMC9484588

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.